# Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

> **NCT03026023** · PHASE4 · WITHDRAWN · sponsor: **Raymond T. Chung, MD**

## Conditions studied

- Cardiac Transplant Disorder
- Hepatitis C

## Interventions

- **DRUG:** Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin

## Key facts

- **NCT ID:** NCT03026023
- **Lead sponsor:** Raymond T. Chung, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** moved forward with another protocol utilizing pan genotypic treatment once it became commercially available and FDA approved
- **Last updated:** 2018-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026023, "Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03026023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*